Results 121 to 130 of about 25,780 (241)

Plasma and tumor topotecan pharmacokinetics (PK).

, 2012
A, Plasma topotecan PK. Abcg2−/− animals, carrying ABCG2-positive tumor T1 (Fig. 2C), were treated with either vehicle +0.5 mg topotecan (green line) or 10 mg Ko143+0.5 mg topotecan (red line) per kg body weight and plasma was collected at 15, 30, 60, 90
Sven Rottenberg (135593), Jos Jonkers (13239), Wendy Sol (135571), Serge A. L. Zander (135568), Lee Greenberger (135576), Piet Borst (8809), Yixian Zhang (135581), Olaf van Tellingen (135587)   +7 more
core   +1 more source

Copper-topotecan complexation : development of a novel liposomal fromulation of topotecan

, 2006
Previously it has been reported that transition metal complexation reactions can be used as a method to encapsulate the anticancer drug doxorubicin into liposomes.
Taggar, Amandeep S.
core   +1 more source

Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas

British Journal of Cancer, 2021
B. Schulte, N. Mohindra, M. Milhem, S. Attia, S. Robinson, V. Monga, A. Hirbe, P. Oppelt, J. Charlson, I. Helenowski, S. Abbinanti, R. Cehic, S. Okuno, B. Van Tine, M. Agulnik   +14 more
semanticscholar   +1 more source

Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma

, 2007
Background: Topotecan is an active agent for the management of untreated and recurrent extensive-disease small cell tung cancer, (ED-SCLC). This study was designed to evaluate the efficacy and safety of a triplet combination with topotecan added to the ...
Tas, Faruk, Aydiner, Adnan, Topuz, Erkan, Derin, Duygu, Camlica, Hakan, Guney, Nese   +5 more
core   +1 more source

A Retrospective Analysis of Topotecan Treatment in Small Cell Lung Cancer

Uludağ Üniversitesi Tıp Fakültesi Dergisi
Small cell lung cancer (SCLC) is a subtype of lung cancer known to be associated with smoking and characterized by poor prognosis. Topotecan, a topoisomerase-1 inhibitor, is an important treatment options used in second-line and later settings for SCLC ...
Alper Coşkun, Eyüp Çoban, Seda Sali, Süreyya Sarıhan, Ahmet Bilgehan Şahin, Adem Deligönül, Erdem Çubukçu, Türkkan Evrensel   +7 more
doaj   +1 more source

Topotecan in platinum-resistant epithelial ovarian cancer

, 2005
Background: Topotecan has been emerged as a new promising anticancer drug for patients with ovarian cancer. Methods: In this study, patients who were treated with topotecan were reviewed retrospectively. A total of 26 patients was included the study. All
Dikmen Y., Akman L., Uslu R., Terek M.C., Goker E., Karabulut B., Sezgin C., Ozsaran A., Sanli U.A.   +8 more
core   +1 more source

Clinical Evidence for Topotecan-Paclitaxel Non–Cross-Resistance in Ovarian Cancer

, 2001
Purpose: A large, randomized study comparing the efficacy and safety of topotecan versus paclitaxel in patients with relapsed epithelial ovarian cancer showed that these two compounds have similar activity. In this study, a number of patients crossed
Phillipe Vennin, Wim ten Bokkel Huinink, Martin Gore, Robert Coleman, J. Carmichael, Marek Spaczynski, Giorgio Bolis, H. Malmström, Graham Ross, M. Spaczynski, J. Malfetano, P. Vennin, S. Z. Fields, J. F. Héron, John Malfetano, M. Gore, A. Gordon, C. Scarabelli, W. ten Bokkel Huinink, Henric Malmström, Claudio Scarabelli, Neville Davidson, N. Davidson, G. Bolis, Jean-François Héron, R. Coleman, G. Ross, James Carmichael, Scott Z. Fields, Alan Gordon   +29 more
core   +1 more source

Immediate Versus Delayed Topotecan after First-line Therapy in Small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2010
Background and objective How to prolong progression free survival (PFS) and overall survival (OS) of patients with small cell lung cancer (SCLC) has been one of the hottest issues. We retrospectively reviewed our data to compare the survival of immediate
Cong XUE, Yuanyuan ZHAO, Liping LIN, Guangchuan XU, Hongyun ZHAO, Yang ZHANG, Wei JIANG, Li ZHANG   +7 more
doaj  

Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan

, 2001
PURPOSE: To compare the efficacy and safety of pegylated liposomal doxorubicin (PLD) and topotecan in patients with epithelial ovarian carcinoma that recurred after or didn’t respond to first-line, platinum-based chemotherapy.
John T. Fleagle, Angel J. Lacave, Alan N. Gordon, Martin E. Gore, David E. Parkin, David Guthrie   +5 more
core   +1 more source

Supplementary File from Overlapping Functions of ABC Transporters in Topotecan Disposition as Determined in Gene Knockout Mouse Models

, 2013
Supplementary File - PDF file 584K, Supplementary Figure 1: Total topotecan pharmacokinetic variables in Abc transporters knock out mouse models at two i.v. dose levels.
Rong Zhang (44942), Amit K. Tiwari (8096816), James M. Gallo (1340688)   +2 more
core   +1 more source